🧵On 3 March 2017, Krzysztof Potempa set up his first biotech called BRAINCURES LTD. Founder Krzysztof Potempa reflects on the journey of turning a curious scientist into a Dreamster with a bold company name and a plan to help others conquer brain diseases here linkedin.com/pulse/fail-fas…

🧵"Venture capital and philanthropy in biotech." I address: What is the relationship between venture capital and venture philanthropy? How many biotechnology companies have benefited from venture philanthropy? What do sceptics of venture philanthropy say? linkedin.com/pulse/venture-…

🧵 Alzheimer’s is a multifactorial disease and probably varies in each individual. We’re going to need precision medicine and combination therapy, which is all of our mantras. Howard Fillit, MD Alzheimer's Drug Discovery Foundation thinks there’s much to learn from gerontology to apply to AD linkedin.com/posts/krzyszto…

1) Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review 2) Repurposed agents in the AD drug development pipeline 5) Artificial intelligence for drug discovery in AD #EndAlz #AlzDiscovery #Alzheimers #Alzheimer #NeuroTwitter linkedin.com/posts/krzyszto…

Executive summary of how the biological intelligence powered BRAINCURES BRAINCURES LTD Discovery Engine (BDE) can advance biomarker- and biology driven drug discovery, repurposing or development of novel or existing treatments for Alzheimer's disease linkedin.com/posts/braincur…

🧵Is Andrew Huberman more scam than science? asks Andrea C. Love, PhD Podcaster and love rat Andrew D. Huberman, Ph.D. is hawking $100 bogus 'unscientific' supplements, scientists warn Caitlin Tilley Podcasting health guru and Stanford University doc is accused of being a womanizer linkedin.com/posts/krzyszto…

🧵Resources that have helped me to understand how to start a biotech? The challenges of building a neuro-focused startup? How to build a platform company? What five CEO behaviors matter? What is the venture capital model? Who are the most active investors? linkedin.com/pulse/how-buil…

🧵Did you know that neurotransmitters are promising immune modulators in the tumor microenvironment? Contact us to harness drugs and targets implicated in learning and memory to advance your quest for biology- and biomarker-driven anti-cancer therapeutics linkedin.com/posts/braincur…

🧵Glioblastoma: BRAINCURES Discovery Engine (BDE)-Targets and -Compounds Prioritize Biomarkers and Treatments. For more details on our phenotypic-big data driven approach to de-risk and accelerate drug development read our primer on biological intelligence linkedin.com/pulse/biologic…

To mark #RareDiseaseDay this review by our Founder & CEO Krzysztof Potempa considers: What is a rare disease? How much does it cost to develop a #raredisease drug? What matters to patients? What can data science approaches (e.g., AI) do for rare diseases? linkedin.com/pulse/rare-dis…

Literature mining of ~2,000 BRAINCURES Discovery Engine assets prioritizes 420 targets and 268 molecules associated with amyotropic lateral sclerosis-ALS also known as motor neuron disease-MND. Prioritized drugs include ropinirole, pimozide, aminophylline linkedin.com/posts/braincur…

Readings for #BrainAwarenessWeek 1) The Cost of Brain Diseases: A Burden or a Challenge? @monicadilucaL monica diluca 2) The Economic Costs of Mental Disorders 3) The Burden of Neurological Disease in the United States: A Summary Report and Call to Action linkedin.com/posts/krzyszto…

Readings for #BrainAwarenessWeek 1. Europe spent €600 million to recreate the human brain in a computer. How did it go? by Miryam Naddaf Miryam Naddaf nature 2. Brain in a box (2012) by Mitch Waldrop #BrainAwarenessWeek2025 linkedin.com/posts/krzyszto…

What has made Alzheimer’s drug development so challenging for the industry? The high-risk, high-reward mindset played a big role too. The belief was, “Yes, it’s risky, but if we succeed, it will be a blockbuster drug.” Those expectations were not realistic pharmaboardroom.com/interviews/joh…

On 2 April 2025 we look forward to presenting the power of the BRAINCURES Discovery Engine platform to accelerate treatments for brain diseases OBN_UK's BioTrinity 2025’s Science Spotlight Thirteen - New Platforms and Technologies for Drug Discovery track linkedin.com/posts/braincur…

🧵To mark Purple Day (26 March) we highlight some of the key readings from the over 192 thousand publications associated with #epilepsy. The recommended readings include: 1) New epilepsy therapies in development 2) Avenues for anti-epileptic drug discovery linkedin.com/posts/braincur…

BRAINCURES LTD Computational prognostic evaluation of Alzheimer's drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches AD master regulators analysis: search for potential targets and drug repositioning candidate linkedin.com/posts/braincur…

To mark #ParkinsonsAwarenessDay during #ParkinsonsAwarenessMonth, BRAINCURES LTD highlighted Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline linkedin.com/posts/braincur…

🧵Long term potentiation-based phenotypic screening of disease linked literature opens a window to treatments for multiple indications. Learn more about our biological intelligence approach here linkedin.com/pulse/biologic…